Novartis AG Gross Profit 2006-2018 | NVS

Novartis AG annual/quarterly gross profit history and growth rate from 2006 to 2018. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Novartis AG gross profit for the quarter ending December 31, 2018 was $8.738B, a 0.73% increase year-over-year.
  • Novartis AG gross profit for the twelve months ending December 31, 2018 was $34.759B, a 5.46% increase year-over-year.
  • Novartis AG annual gross profit for 2018 was $34.759B, a 5.46% increase from 2017.
  • Novartis AG annual gross profit for 2017 was $32.96B, a 3.27% increase from 2016.
  • Novartis AG annual gross profit for 2016 was $31.916B, a 3.23% decline from 2015.
Novartis AG Annual Gross Profit
(Millions of US $)
2018 $34,759
2017 $32,960
2016 $31,916
2015 $32,983
2014 $36,289
2013 $36,137
2012 $36,105
2011 $40,392
2010 $37,073
2009 $32,924
2008 $31,145
2007 $27,915
2006 $25,694
2005 $22,314
Novartis AG Quarterly Gross Profit
(Millions of US $)
Q4 2018 $8,738
Q3 2018 $8,472
Q2 2018 $8,975
Q1 2018 $8,574
Q4 2017 $8,675
Q3 2017 $8,369
Q2 2017 $8,236
Q1 2017 $7,680
Q4 2016 $8,117
Q3 2016 $7,973
Q2 2016 $8,228
Q1 2016 $7,598
Q4 2015 $8,255
Q3 2015 $8,097
Q2 2015 $8,409
Q1 2015 $8,222
Q4 2014 $8,938
Q3 2014 $8,879
Q2 2014 $9,571
Q1 2014 $8,901
Q4 2013 $8,564
Q3 2013 $8,780
Q2 2013 $9,193
Q1 2013 $9,600
Q4 2012 $7,281
Q3 2012 $9,464
Q2 2012 $9,931
Q1 2012 $9,429
Q4 2011 $9,878
Q3 2011 $10,246
Q2 2011 $10,504
Q1 2011 $9,764
Q4 2010 $9,940
Q3 2010 $9,158
Q2 2010 $8,715
Q1 2010 $9,260
Q4 2009 $9,478
Q3 2009 $8,187
Q2 2009 $7,918
Q1 2009 $7,341
Q4 2008 $7,514
Q3 2008 $8,009
Q2 2008 $8,054
Q1 2008 $7,568
Q4 2007 $7,158
Q3 2007 $6,784
Q2 2007 $7,087
Q1 2007 $6,886
Q4 2006 $6,785
Q3 2006 $6,495
Q2 2006 $6,446
Q1 2006 $5,968
Q4 2005 $4,892
Q3 2005 $6,039
Q2 2005 $5,895
Q1 2005 $5,488
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $175.329B $51.900B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $375.338B 17.02
Pfizer (PFE) United States $234.662B 13.14
Merck (MRK) United States $201.136B 17.19
Eli Lilly (LLY) United States $121.698B 21.13
Novo Nordisk (NVO) Denmark $118.902B 19.23
AbbVie (ABBV) United States $116.030B 9.94
Sanofi (SNY) France $104.612B 12.91
GlaxoSmithKline (GSK) United Kingdom $99.770B 13.10
AstraZeneca (AZN) United Kingdom $97.998B 11.18
Bristol-Myers Squibb (BMY) United States $74.051B 11.39